RU2008118008A - Применение lactobacillus для лечения аутоиммунных заболеваний - Google Patents
Применение lactobacillus для лечения аутоиммунных заболеваний Download PDFInfo
- Publication number
- RU2008118008A RU2008118008A RU2008118008/15A RU2008118008A RU2008118008A RU 2008118008 A RU2008118008 A RU 2008118008A RU 2008118008/15 A RU2008118008/15 A RU 2008118008/15A RU 2008118008 A RU2008118008 A RU 2008118008A RU 2008118008 A RU2008118008 A RU 2008118008A
- Authority
- RU
- Russia
- Prior art keywords
- dsm
- use according
- specified
- lactobacillus
- tablets
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract 11
- 241000186660 Lactobacillus Species 0.000 title claims abstract 5
- 229940039696 lactobacillus Drugs 0.000 title claims 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract 12
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract 12
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract 12
- 238000002360 preparation method Methods 0.000 claims abstract 9
- 239000006041 probiotic Substances 0.000 claims abstract 8
- 230000000529 probiotic effect Effects 0.000 claims abstract 8
- 235000018291 probiotics Nutrition 0.000 claims abstract 8
- 239000003826 tablet Substances 0.000 claims abstract 8
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract 6
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
- 239000002775 capsule Substances 0.000 claims abstract 4
- 239000007787 solid Substances 0.000 claims abstract 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract 3
- 208000011231 Crohn disease Diseases 0.000 claims abstract 3
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 3
- 201000004681 Psoriasis Diseases 0.000 claims abstract 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract 3
- 230000007815 allergy Effects 0.000 claims abstract 3
- 230000001363 autoimmune Effects 0.000 claims abstract 3
- 239000007788 liquid Substances 0.000 claims abstract 3
- 210000000056 organ Anatomy 0.000 claims abstract 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 3
- 239000007910 chewable tablet Substances 0.000 claims abstract 2
- 235000015218 chewing gum Nutrition 0.000 claims abstract 2
- 239000011248 coating agent Substances 0.000 claims abstract 2
- 238000000576 coating method Methods 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims abstract 2
- 239000007937 lozenge Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000002245 particle Substances 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- -1 sachets Substances 0.000 claims abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 4
- 235000013305 food Nutrition 0.000 claims 3
- 239000000047 product Substances 0.000 claims 3
- 229920000294 Resistant starch Polymers 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000013325 dietary fiber Nutrition 0.000 claims 2
- 235000021245 dietary protein Nutrition 0.000 claims 2
- 235000021107 fermented food Nutrition 0.000 claims 2
- 235000013312 flour Nutrition 0.000 claims 2
- 102000035122 glycosylated proteins Human genes 0.000 claims 2
- 108091005608 glycosylated proteins Proteins 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 235000021254 resistant starch Nutrition 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 235000015895 biscuits Nutrition 0.000 claims 1
- 235000008429 bread Nutrition 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 235000011868 grain product Nutrition 0.000 claims 1
- 235000015243 ice cream Nutrition 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 235000011837 pasties Nutrition 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 235000013618 yogurt Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/40—Products characterised by the type, form or use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/02—Products made from whole meal; Products containing bran or rough-ground grain
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/06—Products with modified nutritive value, e.g. with modified starch content
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/26—Proteins
- A21D2/267—Microbial proteins
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D8/00—Methods for preparing or baking dough
- A21D8/02—Methods for preparing dough; Treating dough prior to baking
- A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
- A21D8/045—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes with a leaven or a composition containing acidifying bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
- Y10S435/857—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
Abstract
1. Применение по меньшей мере одного штамма пробиотических бактерий Lactobacillus, выбранных из Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, и Lactobacillus plantarum HEAL 99, DSM 15316, Lactobacillus paracasei 8700:2, DSM 13434 и Lactobacillus paracasei 02A, DSM13432 для производства фармацевтической композиции для лечения и/или предотвращения аутоиммунного заболевания. ! 2. Применение по п.1, где указанное аутоиммунное заболевание выбирается из группы, состоящей из органспецифической аутоиммунной реакции, такой, как рассеяный склероз (MS), аллергия, псориаз, ревматоидный артрит, болезнь Крона, неспецифический язвенный колит, сахарный диабет типа 1, воспалительные заболевания кишечника и системная волчанка. ! 3. Применение по п.1, где, по меньшей мере, два пробиотических штамма использованы для лечения и/или профилактики указанного аутоиммунного заболевания. ! 4. Применение по п.2, где, по меньшей мере, два пробиотических штамма использованы для лечения и/или профилактики указанного аутоиммунного заболевания. ! 5. Применение по п.3, где указанные, по меньшей мере, два штамма вводятся последовательно или одновременно. ! 6. Применение по п.4, где указанные, по меньшей мере, два штамма вводятся последовательно или одновременно. ! 7. Применение по любому из пп.1-6, где указанная фармацевтическая композиция представляет собой жидкий препарат или твердый препарат. ! 8. Применение по п.7, где указанный твердый препарат выбирается из группы, состоящей из таблеток, рассасываемых таблеток, леденцов, жевательных таблеток, жевательных резинок, капсул, саше, порошков, гранул, частиц и таблеток с покрытием, таблеток и капсул с кишечно-растворимым покрытием �
Claims (19)
1. Применение по меньшей мере одного штамма пробиотических бактерий Lactobacillus, выбранных из Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, и Lactobacillus plantarum HEAL 99, DSM 15316, Lactobacillus paracasei 8700:2, DSM 13434 и Lactobacillus paracasei 02A, DSM13432 для производства фармацевтической композиции для лечения и/или предотвращения аутоиммунного заболевания.
2. Применение по п.1, где указанное аутоиммунное заболевание выбирается из группы, состоящей из органспецифической аутоиммунной реакции, такой, как рассеяный склероз (MS), аллергия, псориаз, ревматоидный артрит, болезнь Крона, неспецифический язвенный колит, сахарный диабет типа 1, воспалительные заболевания кишечника и системная волчанка.
3. Применение по п.1, где, по меньшей мере, два пробиотических штамма использованы для лечения и/или профилактики указанного аутоиммунного заболевания.
4. Применение по п.2, где, по меньшей мере, два пробиотических штамма использованы для лечения и/или профилактики указанного аутоиммунного заболевания.
5. Применение по п.3, где указанные, по меньшей мере, два штамма вводятся последовательно или одновременно.
6. Применение по п.4, где указанные, по меньшей мере, два штамма вводятся последовательно или одновременно.
7. Применение по любому из пп.1-6, где указанная фармацевтическая композиция представляет собой жидкий препарат или твердый препарат.
8. Применение по п.7, где указанный твердый препарат выбирается из группы, состоящей из таблеток, рассасываемых таблеток, леденцов, жевательных таблеток, жевательных резинок, капсул, саше, порошков, гранул, частиц и таблеток с покрытием, таблеток и капсул с кишечно-растворимым покрытием и рассасываемых полосок и пленок.
9. Применение по п.7, где указанный жидкий препарат выбирается из группы, состоящей из пероральных растворов, суспензий, эмульсий и сиропов.
10. Применение по любому из пп.1-6, где указанная композиция включает носитель.
11. Применение по любому из пп.1-6, где указанная фармацевтическая композиция представляет собой медицинский пищевой продукт, функциональный пищевой продукт, диетическую добавку, питательный продукт или пищевой препарат.
12. Применение по п.10, где указанный носитель независимо выбирается из группы, состоящей из овсяной муки, молочнокислых ферментированных пищевых продуктов, устойчивого крахмала, диетических волокон, углеводов, белков и гликозилированных белков.
13. Применение по п.11, где указанный носитель независимо выбирается из группы, состоящей из овсяной муки, молочнокислых ферментированных пищевых продуктов, устойчивого крахмала, диетических волокон, углеводов, белков и гликозилированных белков.
14. Применение по п.11, где указанный пищевой препарат выбирается из группы, состоящей из напитков, йогуртов, соков, мороженого, хлеба, бисквитов, продуктов из дробленого зерна, батончиков для здорового образа жизни и пастообразных продуктов.
15. Применение по любому из пп.1-6, 8, 9, 12-14, где каждый указанный штамм(ы) присутствует(ют) в композиции в количестве от приблизительно 1×106 до приблизительно 1×1014 КОЕ, предпочтительно от приблизительно 1×108 до приблизительно 1×1012 и более предпочтительно от приблизительно 1×109 до приблизительно 1×1011.
16. Способ лечения аутоиммунного заболевания, где, по меньшей мере, один штамм пробиотических бактерий Lactobacillus, выбранных из Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, и Lactobacillus plantarum HEAL 99, DSM 15316, Lactobacillus paracasei 8700:2, DSM 13434 и Lactobacillus paracasei 02A, DSM13432, вводится индивидууму.
17. Способ по п.16, где указанное аутоиммунное заболевание выбирается из группы, состоящей из органспецифической аутоиммунной реакции, такой как рассеянный склероз (MS), аллергия, псориаз, ревматоидный артрит, болезнь Крона, неспецифический язвенный колит, сахарный диабет типа 1, воспалительные заболевания кишечника и системная волчанка.
18. Способ по п.16 или 17, где, по меньшей мере, два штамма пробиотических бактерий вводятся индивидууму.
19. Способ по п.18, где указанные штаммы вводятся последовательно или одновременно.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0502209 | 2005-10-06 | ||
SE0502209-0 | 2005-10-06 | ||
SE0501150-4 | 2005-10-07 | ||
SE0502250 | 2005-10-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2008118008A true RU2008118008A (ru) | 2009-11-20 |
RU2417092C2 RU2417092C2 (ru) | 2011-04-27 |
Family
ID=37906406
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008118008/15A RU2417092C2 (ru) | 2005-10-06 | 2006-10-06 | Применение lactobacillus для лечения аутоиммунных заболеваний |
RU2008118007/15A RU2440123C2 (ru) | 2005-10-06 | 2006-10-06 | Применение lactobacillus для лечения вирусных инфекций |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008118007/15A RU2440123C2 (ru) | 2005-10-06 | 2006-10-06 | Применение lactobacillus для лечения вирусных инфекций |
Country Status (18)
Country | Link |
---|---|
US (3) | US8936783B2 (ru) |
EP (2) | EP1951273B1 (ru) |
JP (2) | JP5419455B2 (ru) |
KR (2) | KR101300077B1 (ru) |
AU (2) | AU2006297895B2 (ru) |
BR (2) | BRPI0616962B8 (ru) |
CA (2) | CA2624660C (ru) |
CY (1) | CY1118006T1 (ru) |
DK (2) | DK1951273T3 (ru) |
ES (2) | ES2460891T3 (ru) |
HU (1) | HUE030542T2 (ru) |
IN (2) | IN2008DE02606A (ru) |
LT (1) | LT1951272T (ru) |
PL (2) | PL1951272T3 (ru) |
PT (1) | PT1951272T (ru) |
RU (2) | RU2417092C2 (ru) |
SI (1) | SI1951272T1 (ru) |
WO (3) | WO2007040444A1 (ru) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5019961B2 (ja) * | 2006-06-26 | 2012-09-05 | 株式会社ヤクルト本社 | インターロイキン10産生促進剤 |
JP5896589B2 (ja) | 2006-10-02 | 2016-03-30 | デュポン ニュートリション バイオサイエンシーズ エーピーエス | 疾病の罹患率及び持続期間を減少する使用のためのプロバイオティクス |
PL210465B1 (pl) | 2007-06-04 | 2012-01-31 | Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna | Zastosowanie kompozycji szczepów z rodzaju Lactobacillus |
JP2009057346A (ja) * | 2007-09-03 | 2009-03-19 | Kirin Holdings Co Ltd | 免疫バランス調節用組成物 |
FR2922450B1 (fr) * | 2007-10-19 | 2014-06-13 | Lallemand Sas | Utilisation de bacteries lactique pour la prevention et/ou le traitement de pathologies cutanees |
JP2011503104A (ja) | 2007-11-09 | 2011-01-27 | カリフォルニア インスティテュート オブ テクノロジー | 免疫調節化合物ならびに関連組成物および方法 |
EP2153837A1 (en) * | 2008-08-14 | 2010-02-17 | Compagnie Gervais Danone | Compositions comprising Lactobacillus casei for improving resistance to common infectious diseases |
SE533778C2 (sv) | 2009-05-14 | 2011-01-11 | Probi Ab | Probiotisk fruktdryck |
US20100311686A1 (en) * | 2009-06-03 | 2010-12-09 | Kasper Lloyd H | Nutraceutical composition and methods for preventing or treating multiple sclerosis |
WO2011059332A2 (en) | 2009-11-16 | 2011-05-19 | Stichting Top Institute Food And Nutrition | Improved immunomodulation by probiotics |
KR20110082480A (ko) * | 2010-01-11 | 2011-07-19 | 포항공과대학교 산학협력단 | 포유동물 체내에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도 |
CA2787544C (en) * | 2010-01-28 | 2019-07-09 | Ab-Biotics S.A. | Probiotic composition for use in the treatment of bowel inflammation |
DK2555753T3 (en) | 2010-04-07 | 2018-11-26 | California Inst Of Techn | Vesicle for delivering a compound to a mucosal membrane as well as corresponding compositions, methods and systems |
CA2800174A1 (en) | 2010-05-20 | 2011-11-24 | June L. Round | Antigen specific tregs and related compositions, methods and systems |
WO2012081650A1 (ja) * | 2010-12-16 | 2012-06-21 | 株式会社明治 | 遅延型過敏症軽減剤 |
EP2655331A1 (en) | 2010-12-23 | 2013-10-30 | Pfizer Inc | Glucagon receptor modulators |
WO2012093755A1 (ko) * | 2011-01-04 | 2012-07-12 | 포항공과대학교 산학협력단 | 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도 |
WO2012107850A1 (en) | 2011-02-08 | 2012-08-16 | Pfizer Inc. | Glucagon receptor modulator |
JP5261617B2 (ja) * | 2011-03-31 | 2013-08-14 | 森永乳業株式会社 | 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 |
KR101378608B1 (ko) * | 2011-04-13 | 2014-03-27 | 씨제이제일제당 (주) | 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주 |
KR101279852B1 (ko) * | 2011-06-29 | 2013-07-09 | 주식회사 쎌바이오텍 | 골다공증 예방 또는 치료용 조성물 |
US9539281B2 (en) | 2011-07-12 | 2017-01-10 | The Brigham And Women's Hospital, Inc. | Lipid-containing PSA compositions, methods of isolation and methods of use thereof |
KR20140023441A (ko) | 2011-07-22 | 2014-02-26 | 화이자 인코포레이티드 | 퀴놀린일 글루카곤 수용체 조절제 |
US9856451B2 (en) | 2011-12-28 | 2018-01-02 | Yamada Bee Company Inc. | Lactic acid bacterium having IgA production promoting activity, and use thereof |
JP6028962B2 (ja) * | 2012-02-16 | 2016-11-24 | 国立大学法人金沢大学 | ウイルス感染予防乳酸菌組成物及びウイルス感染予防乳酸発酵食品 |
JP5995593B2 (ja) * | 2012-08-02 | 2016-09-21 | 丸善製薬株式会社 | 抗炎症剤 |
WO2014038929A1 (en) | 2012-09-07 | 2014-03-13 | N.V. Nutricia | Probiotics for producing antiviral factors |
FR2997960B1 (fr) * | 2012-11-09 | 2016-08-05 | Inst Nat De La Rech Agronomique (Inra) | Nouvelle souche bacterienne de lactobacillus plantarum et utilisation de cette souche |
WO2014077365A1 (ja) | 2012-11-16 | 2014-05-22 | カルピス株式会社 | 特定のラクトバチルス・ガセリ株又はその処理物を含有するストレス性腸障害の軽減剤 |
CN116889579A (zh) * | 2013-04-03 | 2023-10-17 | 普罗比公司 | 益生菌菌株用于治疗或预防骨质疏松 |
JP2016521284A (ja) | 2013-05-10 | 2016-07-21 | カリフォルニア インスティチュート オブ テクノロジー | 大腸ガンのプロバイオティクスによる防止および処置 |
HUE036025T2 (hu) * | 2013-07-12 | 2018-06-28 | Morinaga Milk Industry Co Ltd | Új tejsav baktérium, gyógyszer, élelmiszer vagy ital, takarmány, amelyek az új tejsav baktériumot tartalmazzák |
TWI505831B (zh) * | 2013-11-15 | 2015-11-01 | Genmont Biotech Inc | 用於治療微小核糖核酸病毒感染的益生菌組合物及其用途 |
TWI505832B (zh) * | 2014-02-21 | 2015-11-01 | Genmont Biotech Inc | 乳酸菌、其組合物與彼等於治療自體免疫疾病暨其倂發症之用途 |
KR101644595B1 (ko) * | 2014-07-11 | 2016-08-03 | 한국식품연구원 | 락토바실러스 파라카제이(Lactobacillus paracasei)를 유효성분으로 포함하는 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물 |
US11331335B2 (en) | 2015-06-10 | 2022-05-17 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
CN108135167B (zh) | 2015-08-19 | 2021-07-09 | 哈佛学院院长及董事 | 脂化psa组合物和方法 |
KR101749222B1 (ko) * | 2016-01-04 | 2017-06-21 | 주식회사 카브 | 젖산균을 유효성분으로 포함하는 인플루엔자 바이러스 예방 및 치료용 조성물 |
AU2017209868B2 (en) * | 2016-01-19 | 2023-08-03 | Probi Ab | Probiotics for use as anti-inflammatory agents in the oral cavity |
EP3196318A1 (en) | 2016-01-19 | 2017-07-26 | Symrise AG | Probiotics for altering the composition of oral biofilms |
GB201600975D0 (en) | 2016-01-19 | 2016-03-02 | Probi Ab | Novel strain of probiotic bacteria and compositions and uses thereof |
EP3222282A1 (en) * | 2016-03-21 | 2017-09-27 | Bionou Research, S.L. | Use of probiotics in the treatment and/or prevention of psoriasis |
EP3484441A4 (en) | 2016-07-15 | 2020-03-18 | President and Fellows of Harvard College | GLYCOLIPID COMPOSITIONS AND METHODS OF USE |
CN106562462A (zh) * | 2016-11-04 | 2017-04-19 | 覃贤强 | 一种富硒保健汤圆及其制备方法 |
WO2018130667A1 (en) * | 2017-01-12 | 2018-07-19 | Probi Ab | Probiotic compositions and uses thereof |
EP3351259A1 (en) | 2017-01-18 | 2018-07-25 | Symrise AG | Probiotics for aggregation with disease-associated species in the oral cavity |
EP3578637A4 (en) * | 2017-01-31 | 2020-12-16 | University - Industry Cooperation Group of Kyung Hee University | NEW LACTIC BACTERIA AND THEIR USE |
SG10202107425VA (en) * | 2017-01-31 | 2021-08-30 | Univ Industry Cooperation Group Kyung Hee Univ | Novel lactic acid bacteria and use thereof |
GB201709763D0 (en) * | 2017-06-19 | 2017-08-02 | Probi Ab | Biological materials and methods |
JP6942030B2 (ja) * | 2017-11-02 | 2021-09-29 | 株式会社ヤクルト本社 | 抗アレルギー剤感受性判定マーカー |
MY186993A (en) | 2018-05-09 | 2021-08-26 | Kobiolabs Inc | Lactobacillus paracasei strain and use thereof |
JP7088573B2 (ja) | 2018-05-23 | 2022-06-21 | コバイオラブズ・インコーポレイテッド | ラクトバチルス・ガッセリーkbl697株及びその使用 |
CA3102445A1 (en) * | 2018-06-18 | 2019-12-26 | Probi Ab | Lactobacillus plantarum compositions and uses thereof |
US20210113633A1 (en) * | 2018-06-18 | 2021-04-22 | Probi Ab | Probiotic compositions and uses thereof |
WO2020001747A1 (en) * | 2018-06-26 | 2020-01-02 | Symrise Ag | Lactobacillus plantarum for skin care |
JP2022506081A (ja) | 2018-10-24 | 2022-01-17 | ノボザイムス アクティーゼルスカブ | ラクトバチルス(lactobacillus)を含む代謝的健康のためのプロバイオティクス補助食品 |
US11058634B2 (en) | 2018-11-19 | 2021-07-13 | Steven J. Edwards | Adherent oral pharmabiotic delivery strip |
JP7130287B2 (ja) * | 2018-12-12 | 2022-09-05 | 生合生物科技股▲ふん▼有限公司 | プロバイオティクス組成物の製造方法 |
GB201905386D0 (en) * | 2019-04-16 | 2019-05-29 | Probi Ab | Probiotic compositions and uses thereof |
IT201900013740A1 (it) * | 2019-08-01 | 2021-02-01 | Nutrilinea S R L | Composition comprising S-adenosyl-L-methionine and a probiotic for use to treat depression |
JP7195714B2 (ja) * | 2020-10-19 | 2022-12-26 | 曽根ファーム株式会社 | 炎症性腸疾患用組成物 |
CN111035663B (zh) * | 2020-01-17 | 2023-07-14 | 广州医科大学附属口腔医院(广州医科大学羊城医院) | 酸鱼乳杆菌10851在制备治疗多发性硬化的药物中的应用 |
IT202000007675A1 (it) * | 2020-04-09 | 2021-10-09 | Sofar Spa | Ivermectina e sue composizioni per uso nel trattamento di infezioni da coronavirus principalmente a carico dell’apparato respiratorio |
WO2021241728A1 (ja) | 2020-05-29 | 2021-12-02 | 国立大学法人東北大学 | 抗ウイルス剤 |
JP2023529152A (ja) | 2020-06-06 | 2023-07-07 | クオラム イノベーションズ リミテッド ライアビリティ カンパニー | コロナウイルス感染を含むウイルス感染を阻害するための物質および方法 |
KR20220091427A (ko) | 2020-12-23 | 2022-06-30 | 주식회사 리스큐어바이오사이언시스 | 락토바실러스 사케아이 유래 세포밖 소포체를 유효성분으로 포함하는 자가면역질환의 개선, 예방 또는 치료용 조성물 |
CN114085798B (zh) * | 2021-12-28 | 2023-10-31 | 杭州普元生物技术有限公司 | 一种植物乳杆菌及其在预防和/或治疗疾病中的应用 |
CN114317343A (zh) * | 2021-12-28 | 2022-04-12 | 杭州普元生物技术有限公司 | 一种植物乳杆菌及其在预防和/或治疗中枢神经系统疾病中的应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4983163A (en) * | 1981-10-09 | 1991-01-08 | Science Research Center, Inc. | Method, compositions and articles for prevention and treatment of herpes simplex virus infections |
JPH092959A (ja) * | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | IgE抗体産生抑制剤および抗アレルギー剤 |
JP4064481B2 (ja) | 1996-10-11 | 2008-03-19 | ハウスウェルネスフーズ株式会社 | 免疫賦活剤 |
JP4163276B2 (ja) * | 1998-02-05 | 2008-10-08 | 独立行政法人理化学研究所 | 機能性組成物 |
KR20010075495A (ko) * | 1998-10-01 | 2001-08-09 | 추후보정 | 산화성 스트레스 인자의 감소 |
EP1020123A1 (en) * | 1999-01-18 | 2000-07-19 | Sitia-Yomo S.p.A. | Beverages containing live lactic bacteria |
EP1165105A1 (en) * | 1999-03-11 | 2002-01-02 | Societe Des Produits Nestle S.A. | Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses |
IT1306716B1 (it) | 1999-06-21 | 2001-10-02 | Mendes S U R L | Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori. |
EP1084709A1 (en) * | 1999-09-17 | 2001-03-21 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Oral recombinant lactobacilli vaccines |
US6696057B1 (en) | 1999-09-22 | 2004-02-24 | Lacpro Industries, Inc. | Composition and method for treatment of gastrointestinal disorders and hyperlipidemia |
SE0003045D0 (sv) * | 2000-08-29 | 2000-08-29 | Probi Ab | New method |
SE0003100D0 (sv) * | 2000-09-01 | 2000-09-01 | Probi Ab | New strains |
FI109602B (fi) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
MXPA04001999A (es) * | 2001-09-05 | 2004-07-16 | Vsl Pharmaceuticals Inc | Bacterias de acido lactico que comprende dinucleotidos de citosina-guanina no metilados para usarse en terapia. |
US20040022775A1 (en) | 2002-04-15 | 2004-02-05 | Gregor Reid | Methods of treating viral infections in mammals |
US20040002275A1 (en) * | 2002-06-28 | 2004-01-01 | Niranjan Thakore | Fabric reinforced rubber product |
JP4034632B2 (ja) * | 2002-10-01 | 2008-01-16 | ハウスウェルネスフーズ株式会社 | 乳酸菌含有炊飯用組成物 |
SE526711C2 (sv) * | 2003-01-31 | 2005-10-25 | Probi Ab | Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav |
WO2004076615A2 (en) | 2003-02-27 | 2004-09-10 | Bioneer A/S | Immunomodulating probiotic compounds |
SE527555C2 (sv) * | 2003-04-04 | 2006-04-11 | Probi Ab | Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar |
DE602004005029T2 (de) * | 2003-05-22 | 2007-11-08 | Synbiotics Ab | Probiotische zusammensetzung mit mindestens zwei milchsäurebakterienstämmen, die zur kolonisierung des magen-darm-trakts fähig sind und in kombination damit die eigenschaften, im darm zu überleben, an den darm zu binden, gegen infektion zu schützen und ballaststoffe zu fermentieren, aufweisen |
WO2005007834A1 (en) * | 2003-07-23 | 2005-01-27 | Probionic Corp. | Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus |
US7842495B2 (en) * | 2003-08-21 | 2010-11-30 | Otsuka Pharmaceutical Co., Ltd. | Lactic acid bacteria capable of stimulating mucosal immunity |
SE0400355D0 (sv) * | 2004-02-17 | 2004-02-17 | Synbiotics Ab | New synbiotec use |
SE528382C2 (sv) * | 2004-10-05 | 2006-10-31 | Probi Ab | Probiotiska lactobacillusstammar för förbättrad vaginal hälsa |
CN101128182B (zh) * | 2004-11-25 | 2011-11-16 | 荷兰联合利华有限公司 | 重链和结构域抗体 |
-
2006
- 2006-10-06 EP EP06799739.5A patent/EP1951273B1/en active Active
- 2006-10-06 DK DK06799739.5T patent/DK1951273T3/da active
- 2006-10-06 KR KR1020087010195A patent/KR101300077B1/ko active IP Right Grant
- 2006-10-06 ES ES06799739.5T patent/ES2460891T3/es active Active
- 2006-10-06 DK DK06799738.7T patent/DK1951272T3/en active
- 2006-10-06 PT PT67997387T patent/PT1951272T/pt unknown
- 2006-10-06 RU RU2008118008/15A patent/RU2417092C2/ru active
- 2006-10-06 CA CA2624660A patent/CA2624660C/en active Active
- 2006-10-06 BR BRPI0616962A patent/BRPI0616962B8/pt active IP Right Grant
- 2006-10-06 AU AU2006297895A patent/AU2006297895B2/en active Active
- 2006-10-06 US US11/992,483 patent/US8936783B2/en active Active
- 2006-10-06 HU HUE06799738A patent/HUE030542T2/en unknown
- 2006-10-06 SI SI200632096A patent/SI1951272T1/sl unknown
- 2006-10-06 RU RU2008118007/15A patent/RU2440123C2/ru active
- 2006-10-06 PL PL06799738.7T patent/PL1951272T3/pl unknown
- 2006-10-06 PL PL06799739T patent/PL1951273T3/pl unknown
- 2006-10-06 WO PCT/SE2006/001137 patent/WO2007040444A1/en active Application Filing
- 2006-10-06 ES ES06799738.7T patent/ES2590916T3/es active Active
- 2006-10-06 CA CA2625074A patent/CA2625074C/en active Active
- 2006-10-06 JP JP2008534491A patent/JP5419455B2/ja active Active
- 2006-10-06 EP EP06799738.7A patent/EP1951272B1/en active Active
- 2006-10-06 WO PCT/SE2006/001138 patent/WO2007040445A1/en active Application Filing
- 2006-10-06 LT LTEP06799738.7T patent/LT1951272T/lt unknown
- 2006-10-06 WO PCT/SE2006/001139 patent/WO2007040446A1/en active Application Filing
- 2006-10-06 US US11/992,488 patent/US8420376B2/en active Active
- 2006-10-06 AU AU2006297896A patent/AU2006297896B2/en not_active Ceased
- 2006-10-06 KR KR1020087010193A patent/KR101300086B1/ko active IP Right Grant
- 2006-10-06 JP JP2008534490A patent/JP5792919B2/ja active Active
- 2006-10-06 BR BRPI0616960A patent/BRPI0616960B8/pt active IP Right Grant
-
2008
- 2008-03-28 IN IN2606DE2008 patent/IN2008DE02606A/en unknown
- 2008-03-28 IN IN2592DE2008 patent/IN2008DE02592A/en unknown
-
2012
- 2012-09-14 US US13/619,146 patent/US8691214B2/en active Active
-
2016
- 2016-09-13 CY CY20161100908T patent/CY1118006T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2008118008A (ru) | Применение lactobacillus для лечения аутоиммунных заболеваний | |
US11723943B2 (en) | Therapeutic use of chardonnay seed products | |
AU2019243093B2 (en) | Nutritional composition, food/drink composition using nutritional composition, and modified milk powder using nutritional composition | |
RU2008104145A (ru) | ПРИМЕНЕНИЕ Lactobacillus ДЛЯ УВЕЛИЧЕНИЯ АДСОРБЦИИ МЕТАЛЛА, ВЫБРАННОГО ИЗ Fe, Zn, Ca И ИХ ИОНОВ | |
RU2009136328A (ru) | Применение lactobacillus plantarum для повышения бактериального разнообразия | |
JP6815410B2 (ja) | 気分プロフィール改善剤 | |
CN102548566A (zh) | 植物乳杆菌菌株用作降血胆固醇试剂 | |
Mustafa et al. | Green technological fermentation for probioticated beverages for health enhancement | |
Jan et al. | Diversity, distribution and role of probiotics for human health: current research and future challenges | |
Pop et al. | Pro and prebiotics foods that modulate human health | |
de Souza et al. | Lean and obese microbiota: differences in in vitro fermentation of food-by-products | |
Karunaratne | Probiotic foods: Benefits to the cereal based Sri Lankan diet | |
Shirsath et al. | Role of Food Supplements in Gut Health | |
US12022844B2 (en) | Nutritional composition, food/drink composition using nutritional composition, and modified milk powder using nutritional composition | |
Bahar et al. | Cookies High in Antioxidants from the Combination of Lactobacillus Reuteri with Mango Juice as a Functional Food Candidate for Children with Functional Digestive Problems | |
EP4289485A1 (en) | Composition having immunostimulatory effect | |
Kılıc | Highlights in probiotic research | |
Rengadu | Microencapsulation of Bifidobacterium animalis and Lactobacillus casei using resistant starch from Vigna unguiculata | |
WO2023217981A1 (en) | Carbon monoxide-releasing molecule (corm) or composition thereof for use in the treatment or the prevention of an intestinal dysbiosis in a subject | |
Passmore | a) Phenylketonuria, Tyrosinemia, Maple Syrup Urine Disease | |
Siti Chairiyah Batubara | turnitin: Cookies High in Antioxidants from the Combination of Lactobacillus Reuteri with Mango Juice as a Functional Food Candidate for Children with Functional Digestive Problems | |
CZ12377U1 (cs) | Potravinový doplněk na úpravu střevní mikroflóry |